Tharimmune, Inc.Tharimmune, Inc.Tharimmune, Inc.

Tharimmune, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.08 M‬USD
−10.91USD
‪−9.32 M‬USD
0.00USD
‪1.46 M‬
Beta (1Y)
−0.47
Employees (FY)
2
Change (1Y)
0
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−4.66 M‬USD

About Tharimmune, Inc.


CEO
Randy D. Milby
Headquarters
Bridgewater
Founded
2017
FIGI
BBG012QFR2V4
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of THAR is 2.13 USD — it has increased by 0.97% in the past 24 hours. Watch Tharimmune, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tharimmune, Inc. stocks are traded under the ticker THAR.
THAR stock has fallen by −1.88% compared to the previous week, the month change is a −21.72% fall, over the last year Tharimmune, Inc. has showed a −72.43% decrease.
We've gathered analysts' opinions on Tharimmune, Inc. future price: according to them, THAR price has a max estimate of 15.00 USD and a min estimate of 15.00 USD. Watch THAR chart and read a more detailed Tharimmune, Inc. stock forecast: see what analysts think of Tharimmune, Inc. and suggest that you do with its stocks.
THAR reached its all-time high on Feb 2, 2022 with the price of 1,590.00 USD, and its all-time low was 1.84 USD and was reached on Oct 7, 2024. View more price dynamics on THAR chart.
See other stocks reaching their highest and lowest prices.
THAR stock is 9.66% volatile and has beta coefficient of −0.47. Track Tharimmune, Inc. stock price on the chart and check out the list of the most volatile stocks — is Tharimmune, Inc. there?
Yes, you can track Tharimmune, Inc. financials in yearly and quarterly reports right on TradingView.
Tharimmune, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
THAR net income for the last quarter is ‪−3.80 M‬ USD, while the quarter before that showed ‪−2.33 M‬ USD of net income which accounts for −63.26% change. Track more Tharimmune, Inc. financial stats to get the full picture.
No, THAR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 2.00 employees. See our rating of the largest employees — is Tharimmune, Inc. on this list?
Like other stocks, THAR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tharimmune, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tharimmune, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tharimmune, Inc. stock shows the sell signal. See more of Tharimmune, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.